14/03/2019

Fidia Pharma USA Inc. announces expansion into Regenerative Medicine markets with launch of NuDYN™

FLORHAM PARK, N.J.--(BUSINESS WIRE)-- Fidia, a world leader in the research, development, and manufacturing of hyaluronic acid (HA)-based products, is introducing NuDYN™, its first product in the regenerative medicine category.
NuDYN™ is a shelf-stable, injectable, flowable amniotic membrane-derived allograft from donated placentas obtained via cesarean delivery. It is processed to be acellular to allow for shelf-stable storage while retaining the beneficial intrinsic properties of the amniotic membrane including hyaluronic acid, collagen, and growth factors. These natural properties of the allograft provide benefits of protection, lubrication, and support.
 

First product in the regenerative medicine category

Health
Products
Website

Find out more about Fidia’s product portfolio:

Go to the website

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint healthcare
- ophthalmology
- wound care
- dermatology
- neurology
- dermo-aesthetics